00000cam 2200000zi 4500 9.965452 CaOODSP 20260925090529 m o d f cr cn||||||||| 250826s2025 onca os f000 0 eng d CaOODSP eng rda CaOODSP eng fre n-cn--- y1y2 H82-66/2025-PDF Wladyka, Blake, author. Insight into approvals, marketing, and pricing of new medicines, 2018 to 2023 / Blake Wladyka and Étienne Gaudette = Aperçu des approbations, de la commercialisation et des prix des nouveaux médicaments, de 2018 à 2023 / Blake Wladyka et Étienne Gaudette. Aperçu des approbations, de la commercialisation et des prix des nouveaux médicaments, de 2018 à 2023 [Ottawa] : Patented Medicine Prices Review Board = Conseil d'examen du prix des médicaments brevetés, [2025] 1 online resource (1 page) : colour illustrations text txt rdacontent computer c rdamedia online resource cr rdacarrier "NPDUIS, National Prescription Drug Utilization Information System." "High-cost specialty medicines are increasingly dominating the landscape of new medicines launched in Canada and around the world. A growing share of these medicines (including biologics, orphan drugs, and oncology products) have annual treatment costs in the tens or hundreds of thousands of dollars. This study provides an overview of new medicine approvals, sales, pricing, characteristics, and access in Canada and internationally"--Objective. Text in English and French. Drug approval Canada Statistics. Drug approval Statistics. Drugs Prices Canada Statistics. Drugs Prices Statistics. Drug accessibility Canada Statistics. Drug accessibility Statistics. Pharmaceutical industry Canada Statistics. Pharmaceutical industry Statistics. Statistics lcgft Canada. Patented Medicine Prices Review Board, issuing body. Insight into approvals, marketing, and pricing of new medicines, 2018 to 2023 / fre (CaOODSP)9.966259 PDF 656 KB https://publications.gc.ca/collections/collection_2026/cepmb-pmprb/H82-66-2025.pdf HTML N/A https://www.canada.ca/en/patented-medicine-prices-review/services/npduis/analytical-studies/posters/insight-approvals-2025poster.html